Patents Examined by Dong Jiang
  • Patent number: 10501536
    Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: December 10, 2019
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
  • Patent number: 10472416
    Abstract: The present invention provides pharmaceutical formulations for anti-IL-17 antibodies. These anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 12, 2019
    Assignee: Eli Lilly and Company
    Inventors: Vincent John Corvari, Barbara Ann Williams, Patrick Daniel Donovan, Aaron Paul Markham
  • Patent number: 10472423
    Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: November 12, 2019
    Assignee: Agency For Science, Technology and Research
    Inventors: Cheng-I Wang, Peter Brauer, Siok Ping Yeo, Hwee Ching Tan, John Edward Connolly
  • Patent number: 10472421
    Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 12, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Peter Brauer, Siok Ping Yeo, Hwee Ching Tan, John Edward Connolly
  • Patent number: 10442857
    Abstract: The present invention relates to the field of medicine, and specifically to the field of monoclonal antibodies against human IL-17. More specifically, the invention relates to monoclonal antibodies/antagonists of IL-17A, which bind with high affinity to an IL-17 epitope, wherein the antibodies contain amino acid substitutions in hypervariable regions of heavy and light chains. The antibodies according to this invention can be chimeric, humanized or human antibodies or antigen-binding fragments thereof, and can be used as a medicinal agent for treating autoimmune and inflammatory disorders and disorders of cell proliferation and development. The invention also relates to methods for producing said antibodies.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 15, 2019
    Assignee: CLOSED JOINT STOCK COMPANY “BIOCAD”
    Inventors: Andrey Borisovich Ulitin, Stanislav Rudolfovich Evdokimov, Valeriy Vladimirovich Soloviev, Yulia Sergeevna Chernyh, Olga Vladimirovna Goncharova, Dmitriy Valerievich Korzhavin, Tatyana Veniaminovna Chernovskaya, Roman Alexeevich Ivanov, Dmitriy Valentinovich Morozov
  • Patent number: 10442869
    Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 15, 2019
    Assignee: CLOSED JOINT STOCK COMPANY “BIOCAD”
    Inventors: Andrey Borisovich Ulitin, Stanislav Rudolfovich Evdokimov, Valeriy Vladimirovich Soloviev, Yulia Sergeevna Chernyh, Olga Vladimirovna Goncharova, Dmitriy Valerievich Korzhavin, Tatyana Veniaminovna Chernovskaya, Timofey Aleksandrovich Nemankin, Roman Alexeevich Ivanov, Dmitriy Valentinovich Morozov, Victoria Mikhailovna Ekimova, Ekaterina Vladimirovna Sofronova, Yakov Yurevich Ustyugov
  • Patent number: 10434172
    Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: October 8, 2019
    Assignee: Novartis AG
    Inventors: Charis Papavassilis, Oliver Sander, Tomohiro Shima, Susumu Kitamura
  • Patent number: 10416172
    Abstract: The present invention relates to an isolated naturally-occurring soluble truncated IL-23R? protein, which is a translated protein resulting from a mRNA splice variant of IL-23R?. The soluble IL-23R? proteins (e.g., ?9 and ?8,9) represents a novel soluble IL-23R? protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that ?9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23R? protein. More importantly, the present invention provides an utility application of the ?9 and ?8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, ?9 and ?8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of ?9 and ?8,9 in treating a human patient inflicted with Crohn's disease.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: September 17, 2019
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
  • Patent number: 10393748
    Abstract: A biomarker for predicting and/or monitoring the efficacy of a c-Met inhibitor; a composition for predicting and/or monitoring the efficacy of a c-Met inhibitor, comprising a material detecting the biomarker; a composition for selecting a subject suitable for the application of a c-Met inhibitor, comprising a material detecting the biomarker; a method for predicting and/or monitoring the efficacy of a c-Met inhibitor using the biomarker; a method for selecting a subject suitable for the application of a c-Met inhibitor using the biomarker; and a method for preventing and/or treating cancer comprising administering a c-Met inhibitor to the selected subject.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: August 27, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Soo Yeon Jung, Seon Hui Shim, Yun Jeong Song, Hyeon-seok Yoo
  • Patent number: 10363307
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Novartis AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • Patent number: 10358489
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: July 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • Patent number: 10358490
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Patent number: 10358477
    Abstract: The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: July 23, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Yannick Jacques, Ariane Plet, Erwan Mortier, Agnes Quemener, Patricia Vusio
  • Patent number: 10344079
    Abstract: The invention relates to an antibody-drug conjugate and an immunocytokine for use in the treatment of a neoplastic or inflammatory disease, as well as molecules comprising an antibody-drug conjugate and an immunocytokine.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: July 9, 2019
    Assignee: PHILOGEN S.P.A.
    Inventors: Giulio Casi, Katrin Gutbrodt, Dario Neri
  • Patent number: 10336801
    Abstract: The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a TNF-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: July 2, 2019
    Assignee: NATIONAL CHUNG HSING UNIVERSITY
    Inventors: Shiow-Her Chiou, Kuan-Chih Chow, Jui-Hung Shien, Yi-Hsin Fan, Pei-Hua Lin, Pei-Shan Wu
  • Patent number: 10308723
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: June 4, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Patent number: 10246512
    Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: April 2, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Peter Brauer, Siok Ping Yeo, Hwee Ching Tan, John Edward Connolly
  • Patent number: 10202433
    Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 12, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Nantes, Centre National de la Recherche Scientifique (CNRS), Universite D'Angers
    Inventors: Yannick Jacques, Erwan Mortier, Agnes Quemener, Ariane Plet
  • Patent number: 10167338
    Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 1, 2019
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Cheng-I Wang, Peter Brauer, Siok Ping Yeo, Hwee Ching Tan, John Edward Connolly
  • Patent number: 10160793
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 25, 2018
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang